This site is intended for healthcare professionals
EMC Drug Feed
Drug information

Bacteriostatic Saline for Injection

POM
Read time: 1 mins
Last updated: 03 May 2019
...
 

Summary of product characteristics


1. Name of the medicinal product

Bacteriostatic Saline for Injection


2. Qualitative and quantitative composition

Each vial contains sodium chloride, 0.9% w/v.

Excipient(s) with known effect

Each vial contains benzyl alcohol, 0.9% w/v.

For the full list of excipients, see section 6.1.


3. Pharmaceutical form

Sterile Solution


4.1. Therapeutic indications

To be used to reconstitute Prostin E2 Sterile Solution 10 mg/ml.


4.2. Posology and method of administration

Extra-amniotic only.


4.3. Contraindications

Not applicable.


4.4. Special warnings and precautions for use

Not applicable.


4.5. Interaction with other medicinal products and other forms of interaction

Not applicable.


4.6. Fertility, pregnancy and lactation

Not applicable.


4.7. Effects on ability to drive and use machines

Not applicable.


4.8. Undesirable effects

Benzyl alcohol is contained in the diluent and has been reported to be associated with a fatal "gasping syndrome" in premature infants.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


4.9. Overdose

Not applicable.


5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Solvents and diluting agents, incl. irrigating solutions, ATC code: V07AB


5.2. Pharmacokinetic properties

Not applicable.


5.3. Preclinical safety data


6.1. List of excipients

Benzyl alcohol

Sterile water for injection


6.2. Incompatibilities

Not applicable.


6.3. Shelf life

5 years.


6.4. Special precautions for storage

Store below 25°C. Discard any remaining solution after use.


6.5. Nature and contents of container

Type I flint glass vials and rubber closures (EP) which are sealed with a flip-top aluminium cap. Vials contain 18.5 ml or 50 ml.


6.6. Special precautions for disposal and other handling

No special requirements.


7. Marketing authorisation holder

Pfizer Limited

Ramsgate Road

Sandwich

Kent

CT13 9NJ

UK


8. Marketing authorisation number(s)

PL 00057/1513


9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 15 February 1990

Date of latest renewal: 23 May 2003


10. Date of revision of the text

04/2019

Ref: BA 4_2

4.1 Therapeutic indications

To be used to reconstitute Prostin E2 Sterile Solution 10 mg/ml.

4.2 Posology and method of administration

Extra-amniotic only.

4.3 Contraindications

Not applicable.

4.4 Special warnings and precautions for use

Not applicable.

4.5 Interaction with other medicinal products and other forms of interaction

Not applicable.

4.6 Fertility, pregnancy and lactation

Not applicable.

4.7 Effects on ability to drive and use machines

Not applicable.

4.8 Undesirable effects

Benzyl alcohol is contained in the diluent and has been reported to be associated with a fatal "gasping syndrome" in premature infants.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).